Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2018 08:33 ET | Source: Achaogen, Inc.

UPDATE -- ZEMDRI™ (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ...
June 26, 2018 08:00 ET | Source: Achaogen, Inc.

ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)

― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ...
June 11, 2018 08:01 ET | Source: Achaogen, Inc.

Achaogen Highlights Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
May 24, 2018 08:01 ET | Source: Achaogen, Inc.

Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2018 Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
May 04, 2018 07:30 ET | Source: Achaogen, Inc.

Achaogen Reports First Quarter 2018 Financial Results and Provides Corporate Update

-- FDA Advisory Committee voted in favor of plazomicin for treatment of adults with complicated urinary tract infections -- -- Conference call today at 8:30 a.m. Eastern Time -- SOUTH SAN FRANCISCO,...
May 02, 2018 17:12 ET | Source: Achaogen, Inc.

Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract Infections

SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
May 02, 2018 07:05 ET | Source: Achaogen, Inc.

Achaogen Stock Trading Halted Today

SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
April 26, 2018 08:01 ET | Source: Achaogen, Inc.

Achaogen Wins CARB-X Funding Award to Advance Development of Novel Aminoglycoside to Fight Highly-Resistant Infections

-- CARB-X funding to support Achaogen’s early-stage aminoglycoside program developing antibiotics for difficult to treat infections that are associated with high mortality -- -- Awarded Up to $2.4...
April 25, 2018 08:01 ET | Source: Achaogen, Inc.

Achaogen to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 4, 2018

SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
April 23, 2018 08:01 ET | Source: Achaogen, Inc.

Achaogen Highlights Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

-- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae -- SOUTH SAN FRANCISCO, Calif.,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right